- Language: English
- 70 Pages
- Published: January 2013
- Region: Global
Dementia: Causes, Treatments, and Outlook 2011
- Published: August 2011
- Region: Global, United States
- 67 Pages
- UBM Canon
Neurodegenerative diseases are the sixth-leading cause of death in high-income countries, with 35.6 million people suffering from dementia worldwide. This patient population is predicted to reach 115.4 million people by 2050. Up to 8% of all people over 65 years old have some form of dementia. Dementia prevalence about doubles for every five years of age starting at 60. Dementia caused by nervous system diseases, especially Alzheimer's disease, is increasing in frequency. Alzheimer's disease strikes nearly a half million new patients each year. There are only a handful of FDA-approved drugs for the treatment of Alzheimer's disease.
These drugs temporarily reduce symptoms including memory problems, confusion, aggression, and a general decline in bodily functions. These medicines work by slowing down the disease activity that breaks down a key neurotransmitter or by regulating the activity of glutamate, a chemical messenger involved in learning and memory. Industry experts hope for a breakthrough Alzheimer's drug that will treat the underlying disease and stop or delay the cell damage that eventually leads to worsening of symptoms. A drug that can stop or reduce memory loss could generate annual sales exceeding $5 billion. Pfizer Inc. and Eisai Co. Ltd.'s Aricept is the top-selling drug for the treatment of dementia. Aricept is the first and only prescription medication approved by the FDA for the treatment of all stages of AD - mild, moderate and severe dementia of the Alzheimer's type.
Aricept is not a cure for AD, but may help provide symptomatic benefits for some patients. For those who respond, symptoms may improve, stabilize or progress more slowly than patients who do not take Aricept.
Aricept generated 2010 global sales of about $3.97 billion. Since Pfizer's loss of exclusivity in November 2010, other companies such as Teva are shipping generic versions of the top-selling medication.
This special report focuses on the market leaders for dementia as well as the products in development anticipated to head this area in the years to come. This compilation’s prescription-product pipeline details the following information for each medicine: chemical or substance composition, intended indication, class of drug, clinical status, region of development, and the product developer/intended marketer. Pipeline status details preclinical development, Phase I, Phase I/II, Phase II, Phase II/III, Phase III, and awaiting approval. Regions of development include the United States, Europe, and Japan. A directory of dementia prescription-drug developers and marketers is included.
Additionally provided in this report is a listing of dementia medical-device entries, sorted by device class, as well as a directory of medical-device companies associated with the dementia field. SHOW LESS READ MORE >
Table of contents
- Dementia Market Overview
- Dementia and Related Conditions Companies Review
- Dementia-Related Rx Drug and Biologic Pipeline
- Awaiting Approval
- Phase III
- Phase II/III
- Phase II
- Phase I/II
- Phase I
- Developers and Marketers for Dementia-Related Rx Drugs/Biologics
- Dementia-Related Devices
- Class I
- Dementia-Related Device Companies